University of Arkansas, Fayetteville

ScholarWorks@UARK
Chemical Engineering Undergraduate Honors
Theses

Chemical Engineering

12-2013

Manufacturing the next generation of vaccines: non-egg based
platform for influenza vaccine
Andrew B. Price
University of Arkansas, Fayetteville

Follow this and additional works at: https://scholarworks.uark.edu/cheguht

Citation
Price, A. B. (2013). Manufacturing the next generation of vaccines: non-egg based platform for influenza
vaccine. Chemical Engineering Undergraduate Honors Theses Retrieved from
https://scholarworks.uark.edu/cheguht/51

This Thesis is brought to you for free and open access by the Chemical Engineering at ScholarWorks@UARK. It has
been accepted for inclusion in Chemical Engineering Undergraduate Honors Theses by an authorized administrator
of ScholarWorks@UARK. For more information, please contact scholar@uark.edu.

Manufacturing the Next Generation of Vaccines:
Non-egg Based Platform for Influenza Vaccine

An Undergraduate Honors College Thesis
in the

Department of Chemical Engineering
College of Engineering
University of Arkansas
Fayetteville, AR

by

Andrew B. Price

December 13, 2013

This thesis is approved.
Thesis

Advisor: &/*tl

Thesis Committee:

i c^,.^:c i-Ftf

Briile

For my honors thesis project, I formed a group with two other chemical engineering students,
Nathan Havens and Chris Walls, to complete the AIChE 2014 student design competition problem
dealing with designing a vaccine production facility that uses a non-egg based expression platform. My
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Letter of Transmittal
Nathan Havens, Andrew Price, Christopher Walls
Ralph E. Martin Department of Chemical Engineering
University of Arkansas-Fayetteville
American Institute of Chemical Engineers
120 Wall St.
New York, NY 10005
Dear reader,
The enclosed contains design information for a manufacturing facility that will produce influenza vaccine
using an Sf9 insect cell expression platform rather than the traditional egg-based platform. Advantages to
this approach include faster times to market and increased production. This report shows that the process
is economically viable and indeed very profitable. The facility is designed to produce 60 million trivalent
vaccine doses per year which covers over one third of the market.
Consider this report only a preliminary design. More research on market conditions and the production
process is to be done to be ready for a full-scale launch. However, this report does show that there is
exciting and profitable opportunity for a company on the leading edge of these new vaccine production
methodologies.
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I: Abstract
This report explores the design of an influenza vaccine manufacturing facility using a non-egg
based expression platform. The current standard procedure in flu vaccine production is to grow the virus
in bird eggs. However, recently there is evidence that supports production by other expression
platforms. The Sf9 insect cell is considered in this report. Facility design including cell culture media
formulation through product storage for shipment and final formulation is considered based on the use
of an existing facility. The new design also employs the use of disposable equipment such as bioreactors
and purification unit operations. These disposables help reduce production time and are an
economically viable option.
Market trends are analyzed, and it is concluded that production capabilities for this proposed
facility should be about 60 million doses per year to accommodate one third of the market and be able
to account for potential epidemics. At this production, revenue is approximately $391 million per year.
Capital costs are very low due to the use of the existing facility, and manufacturing costs are also very
reasonable even with the use of disposable equipment. Based on a 10 year project lifetime, the NPV for
the project is approximately $460 million. The project is economically robust when considering various
factors such as fluctuating dosage selling price, dosage demand, and manufacturing costs.
A major concern for the profitability of this project is if the market will accept large quantities of
vaccine produced by new methods that are not historically tested and proven to work. More research
should conducted to determine how the market will react to such changes.
The next step in the design process is to conduct laboratory and pilot-scale tests to determine
more exact cell and virus growth curves for the seed train and the bioreactors. Once this information is
collected, more precise designs can be formulated. Based on the considerations in this report, the
production of influenza vaccine using the Sf9 expression platform is viable both economically and in its
ability to meet market demands in a timely manner. Companies on the leading edge of this development
will have a great deal to gain.
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II: Introduction
Many new challenges and opportunities have arisen in the field of vaccine production in the
twenty-first century. Increased product demand, concerns about product quality, and a greater focus on
reducing environmental impact are a few of the challenges facing the biopharmaceutical industry [13].
However, with each of these challenges comes an opportunity for ingenuity and development within the
industry. One area of increased focus within the industry has been that of developing non-egg based
platforms for the production of influenza vaccines. The traditional expression platform for influenza
vaccine development is bird eggs. This process has proven to be safe, reliable, and adaptable to World
Health Organization (WHO) yearly standards. However, the egg-based platform also comes with risks
including a potential sudden decrease in supply due to a bird flu outbreak and patient allergies to eggs
and feathers [7].
Recent developments in equipment and technology have made Chinese hamster ovary and
insect cell expression systems realistic options for influenza vaccine production platforms [5,4]. These
cell-based expression systems may offer increased production and faster times to market for the
vaccines people need. The major drawback to these platforms is that they have not been used
extensively in large-scale production like the egg-based platform. However, the initial investment of
time, research, and financial recourses may prove to be very profitable for companies on the leading
edge of this development.
This report contains preliminary design information for an existing production facility that is
being transitioned to produce a trivalent influenza vaccine using the Sf9 insect cell expression system
[4]. The purpose of this design report is to provide enough information for management to determine if
this is a suitable production method to pursue. The design provides a general scope of the process from
the preparation of cell culture media to final product purification. Final formulation and product
packaging are mentioned but not considered in depth. Equipment specifications and process economics
are also discussed. A brief discussion of traditional clean-in-place equipment and newer disposable
equipment is also contained in this report.
III: Process Description
The Process Flow Diagram (PFD) and overall material balance for the process are shown in
Figure 1 below. The process consists of cell culture media preparation and scale-up seed train, virus
inoculation and growth in production bioreactors, virus recovery and purification, and product storage.
The product would then be shipped to the final formulation group for formulation and packaging.
Cell Culture Media Formulation
There are several options for appropriate cell culture media. One option that suits the needs for
this process is “Grace’s insect media” developed by Life TechnologiesTM. The media is prepared onsite by
mixing media powder with water in M-101 according to the procedure provided by Life
TechnologiesTM[9]. The mixer uses disposable pre-sterilized bags each containing 40 L of culture media.
Seed Train
To begin the seed train, 1 L of culture media is added to a flask along with a vial of 1 x 107 viable
Sf9 insect cells. The scale up process takes approximately 160 hours per batch. The cells are expanded
3

4
11

S-103

2

1

12

M-101

3

13

S-104

10

14

SP-102 A/B/C

18

4

E-101

Insect Cell Vial

SP-101 A/B/C

SP-102 A/B/C
Incubator

S-103
Ion-Exchange
Chromatography

S-104
Sterile
Filtration

17

15

Water
Product
Waste

R-101

5

Virus

E-101
Refrigerator

R-101
Bioreactor

Figure 1: Process flow diagram and overall material balance for a single monovalent
batch of the vaccine production process
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by batch wise addition into larger volumes of media over time up to the final volume of 40 L. Over this
time period, the cells are incubated to provide maximum growth rate. Once the final scale-up is
completed, the mixture is ready for the production bioreactor.
Production Bioreactor
The Sf9 culture broth is added to the bioreactor and inoculated with the particular strand of
influenza virus being used in the batch. Although the vaccine being produced is trivalent, only a single
moiety of the vaccine can be produced in each batch. The bioreactor (R-101) uses disposable 50 L bags
to contain each 40 L batch. Each batch remains in the bioreactor for 50 hours. For the purposes of this
design it was assumed that the Sf9 cells follow a typical growth curve as shown below in Figure 2 [1].

Figure 2: Typical cell density growth curve for Sf9 insect cells in a batch culture [1]

The first 160 hours represent scale-up in the seed train. Inoculation occurs at the 160 hour
point. The next 50 hours account for virus production in the bioreactor. The broth is removed from the
bioreactor at 210 hours. Again, this setup is based on a typical growth curve for Sf9 cells. If this
production method is pursued, it would be quite necessary to employ laboratory and pilot scale
operations to determine growth rates in the specific equipment used for this process as well as
optimum conditions for the seed train scale-up and virus production in the bioreactor.
Recovery, Purification, and Inactivation of Product
Three unit operations are used for recovery and purification of the product. Normal-flow
filtration (S-101) is first used to remove the biomass from the product. Cross-flow filtration is then used
to begin the purification process. Anion exchange chromatography (S-103) is used to complete the
purification process. This method is widely accepted in the vaccine production industry and
recommended specifically by GE HealthcareTM[3].
For the inactivation process, it is necessary to select a method that safely inactivates the virus
without destroying the product. The method used in this design is sterile filtration (S-104). Each of the
5

purification and inactivation techniques employ disposable cartridges rather than traditional clean-inplace vessels.
Storage and Shipment
The final product from each batch will be freeze dried for proper storage according to CDC
recommendations [12]. The product will be stored in its individual moieties. At this point in the process,
the moiety products will be ready for shipment to the final formulation group as the market demands.
Final formulation of the trivalent vaccine and packaging for patients will occur at this point. This final
step in the process is outside the scope of this report and can be handled by the professionals in the
formulation group as demand requires.
Production Waste
This report investigates using a current facility for a new method of production. Therefore, it is
assumed that the current sewer system and “kill tank” systems can be employed for the safe and
reliable handling of all production waste from this process.
Sample Analysis
Sample analysis and quantification is extremely important to maintain product quality.
Equipment designed for this purpose may be available on site. If not, the Biacore T200 manufactured by
GE HealthcareTM is a viable option.
Batch Scheduling
The rate-limiting steps in the production process are the seed train and the bioreactors.
Therefore, a general scheduling procedure can be outlined from these two steps in the process. A
sample batch schedule for the seed train and bioreactor is shown below in Figure 3. The time required
to produce the total required amount of a single moiety is approximately 35 days (840 hours). The time
required to produce all of the required moieties is approximately 105 days.

Figure 3: Sample seed train and bioreactor batch schedule for the complete production cycle of a single moiety
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The time required for the seed train for each batch is 160 hours. In addition, it is assumed that 8
hours of cleaning, sterilizing, and preparing for the new batch will be required for each batch since
traditional clean-in-place vessels are used in this part of the process. The time required in the bioreactor
is 50 hours. With a 6 hour time period between each batch, the time in the bioreactor is one third of the
time required in the seed train. Therefore, production time can be optimized by having three
independent seed trains running at once. This is reflected by seed trains A, B, and C in Figure 3. The
sequence for each batch in the bioreactor is also shown in Figure 3. The three independent seed trains
are not indicated in the PFD in Figure 1 because this diagram is designed on a “per batch” basis.
Disposable Equipment vs. Clean-in-Place Equipment
There has been a recent shift in biopharmaceutical manufacturing towards disposable
equipment [8]. Advantages of this technology include reduced capital investments, faster facility
construction and launch, and reductions in time and costs for equipment sterilizations. However,
traditional clean-in-place equipment has been proven effective for many years and requires a
significantly lower consumables budget for manufacturing. The process design in this report employs
both traditional and disposable equipment. Clean-in-place vessels are used in the seed train. Most other
parts of the process use disposable equipment for the reasons outlined above. As this new equipment
becomes more popular and widespread, production costs will likely decrease which will help eliminate
the major drawback of a much greater consumables budget.
IV: Utility Requirements
One major advantage of using disposable equipment is the elimination of steam required for
cleaning and sterilizing process vessels. The major utility requirements for this facility would be water
and power. The power requirements for the facility are not estimated in this report because the cost is
assumed to be insignificant at this stage in the design process. Further investigation into utility costs can
be done if plans for this facility advance in the future. Water requirements are estimated and accounted
for in the economics section of this report.
V: Equipment Specifications
The equipment specification sheet is shown on the next page in Figure 4. This specification sheet
represents the necessary purchases for transitioning the facility to a non-egg based expression platform.
Other equipment is required for the process but is assumed to be on site. This includes sample analysis
equipment, “kill tank” systems for pre-sewage treatment, and miscellaneous equipment. Other
equipment required for purchase that is not included in the PFD or equipment specifications sheet is a
number of small flasks for the seed train scale-up procedure.
The bioreactors and separation equipment were all chosen from GE Healthcare’s line of
disposable vaccine production equipment. Purchasing the majority of the equipment from a single
manufacturer will improve compatibility and customer service should any issues arise.
VI: Equipment Cost and Fixed Capital Investment Summary
Since the facility for this production process already exists, the Fixed Capital Investment (FCI) for
this project will consist of only new capital equipment purchases. A summary of the capital costs for this
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Mixers
M-101
WAVE mixer manufactured by GE
Dimensions: 0.50 m x 0.38 m x 0.17 m
Maximum operating volume: 35 L
Use M*Bag
Volume: 35 L
Material: Plastic
Reactors
R-101
WAVE bioreactor manufactured by GE
Stainless steel
Dimensions: 1.85 m x 1.09 m x 1.12 m
Use Cellbag Bioreactors
Volume 50 L
Material: Plastic
Special Purpose Equipment
SP-101 A/B/C, 102 A/B/C*
Incubator manurfactured by Cole-Parmer
Stainless steel
Temperature range: 5 C to 105 C
Capacity: 24.79 cuft
Chamber dimensions: 39.5 in x 52.6 in x 20.6 in
*There are 6 total incubators employed simultaneously,
but only 2 are used on a per batch basis
Refrigeration
E-101
HM LY series pharmaceutical vacuum freezing dryer
Manufactured by HM Pharmachine
Condenser temperature: -70 C
Cooling rate: 20 to 40 C per 45 min
220 V

Separators
S-101
Ulta Prime GF manufactured by GE
Normal flow filtration
Area: 0.56 square meters
Pore size: 0.6 micron
Glass microfiber filtration membrane
10 inch capsule length
S-102
AKTAcrossflow manufactured by GE
Cross flow filtration
Dimensions: 0.62 m x 0.40 m x 0.65 m
Use AXM/AXH ultrafiltration cross flow cartridges
Material: polysulfone
Membrane area: 42 square cm
S-103
AKTA Ready Flow Kit manufactured by GE
Ion (anion) exchange chromatography
Use Capto Q chromatography cartridges
Bed dimensions: 80 mm x 200 mm
Highly cross-linked agarose matrix
S-104
Ulta Pure SG
Sterile Filtration
Area: 0.047 square meters
Pore size: 0.2 micron
Polyethersulphone membrane material

Figure 4: Equipment specification sheet

process is given on the next page in Table 1. The prices are based on online prices or direct quotes from
the manufacturer.
The total FCI for the process is $1 million. This number is obviously low for a pharmaceutical
facility, but it should be considered that the vast majority of the FCI would have been incurred in the
purchase of land and building of the actual facility. The most significant costs are the freeze dryer,
sample analysis equipment, and bioreactor.
VII: Manufacturing Costs
A summary for the annual manufacturing costs for the process is given on the next page in Table
2. The total annual Cost of Manufacturing (COM) is $2.8 million. The largest piece of that total by far is
the operating labor costs due to the extremely precise nature of the process. Prices for Grace’s insect
media and disposable equipment were found online. The price of water was set to the standard value.
Operating labor costs were calculated as outlined in Turton’s process design text [11].
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Table 1: Summary of the FCI for the new vaccine production process

Item
WAVE Mixer
Spinner Flasks (6L)
Incubator
WAVE bioreactor
Cross Flow Filtration Machine
Chromatography add-on for CFF machine
Sample analysis machine
Freeze dryer
Freezer
Total

Total Quantity
1
30
6
1
1
1
1
1
2

$
$
$
$
$
$
$
$
$

Unit Cost
9,889.00
950.00
8,900.00
190,190.00
81,102.00
8,100.00
367,400.00
200,000.00
9,833.00

$
$
$
$
$
$
$
$
$
$

Total Cost
9,889.00
28,500.00
53,400.00
190,190.00
81,102.00
8,100.00
367,400.00
200,000.00
19,666.00
958,247.00

Table 2: Summary of annual manufacturing costs for the new vaccine production process

Item
Grace's Insect Media
WAVE Mixer M*Bags
Reactor cellbags (50L)
Normal Flow Filters
Cross Flow Filtration Cartridges
Chromatography cartridges
Sterile filtration cartridges
Water for Injection (L)
Operating labor
Sterilization
Total

Total Quantity
$
108.00
$
36.00
$
36.00
$
36.00
$
72.00
$
36.00
$
36.00
$
1,800.00

$
$
$
$
$
$
$
$

Unit Cost
Total Cost
87.00 $
9,396.00
122.00 $
4,392.00
233.00 $
8,388.00
224.00 $
8,064.00
216.00 $
15,552.00
11,832.00 $
425,952.00
388.00 $
13,968.00
1.00 $
1,800.00
$ 2,018,857.00
$
347,000.00
$ 2,853,369.00

VIII: Market Conditions and Revenue Analysis
Demand for influenza vaccine has increased sharply over the past decade as shown in Figure 5
[6]. The CDC reports that in the 2013-2014 flu season about 145 million vaccine doses will be produced
[10]. If this trend continues for the next flu season, it is reasonable to assume that about 150 million
doses of vaccine will be produced in the 2014-2015 season. To support one third of the market, a major
pharmaceutical company could produce about 50 million doses of vaccine. To account for a potential
epidemic, production capabilities should be at 60 million doses. This assumption of 60 million doses
produced will be carried through the rest of the economic analysis in this report. The calculation method
for determining the number of batches to process to account for 60 million doses is shown in Appendix
A.
The base revenue for this facility is determined simply by the number of doses produced
multiplied by a constant selling price per dose. According to the CDC, the flu vaccine price per dose is
about $10.85 [2]. Assuming a wholesale rate of 60% of that market price, the price per dose of vaccine
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sold would be $6.51. Using this constant price and a value of 60 million doses, yearly revenue would be
$391 million.

Figure 5: Market trend of influenza vaccine supply and distribution since 2003 [6]

IX: Economics Analysis
The analysis presented here is based on a 10 year project lifetime with one year of setup
required. An internal rate of return (IRR) of 50% is used along with a tax rate of 40%. A working capital of
30% of the FCI is used. The economic analysis for this base case scenario is presented below in Table 3.
Years 5-8 were removed from the chart for the purposes of this report. The full economic analysis chart
is available in Appendix B. The analysis folows the method outlined in Turton’s process design text [11].
Table 3: Base case economic analysis for the proposed production facility
End of Year (k)
Investment
Depreciation (dk)
FCIL-∑dk
Revenue
COM
(R-COM-dk)*(1-t)+dk
Cash Flow (CF)
Cumulative CF
Discounted CF
Cumulative Discounted CF

$
$
$
$
$
$
$
$
$
$

0
(958,247.00)
(958,247.00)
(958,247.00)
(958,247.00)
(958,247.00)

1
$
$
$
$
$
$
$
$
$
$

191,649.40
766,597.60
390,600,000.00
2,853,369.00
232,724,638.36
232,724,638.36
231,766,391.36
155,149,758.91
154,191,511.91

2
$
$
$
$
$
$
$
$
$
$

306,639.04
459,958.56
390,600,000.00
2,853,369.00
232,770,634.22
232,770,634.22
464,537,025.58
103,453,615.21
257,645,127.11

3
$
$
$
$
$
$
$
$
$
$

$
183,983.42 $
275,975.14 $
390,600,000.00 $
2,853,369.00 $
232,721,571.97 $
232,721,571.97 $
697,258,597.55 $
68,954,539.84 $
326,599,666.96 $

4
$
110,390.05 $
165,585.08 $
390,600,000.00 $
2,853,369.00 $
232,692,134.62 $
232,692,134.62 $
929,950,732.17 $
45,963,878.44 $
372,563,545.40 $

9
958,247.00
390,600,000.00
2,853,369.00
232,647,978.60
232,647,978.60
2,093,256,859.20
6,051,707.82
452,378,195.34

10
$
$
$
$
$
$
$
$
$
$

$
958,247.00 $
390,600,000.00 $
2,853,369.00 $
232,647,978.60 $
232,647,978.60 $
2,325,904,837.80 $
4,034,471.88 $
456,412,667.22 $

11
958,247.00
390,600,000.00
2,853,369.00
232,647,978.60
232,647,978.60
2,558,552,816.40
2,689,647.92
459,102,315.14

The net present value (NPV) for the project is $459 million after a 10 year lifetime. This is quite
impressive, but again it must be considered that the capital costs are considerably low due to the use of
an existing facility. Even so, it is clear that the new production process outlined in this report is quite
profitable.
Sensitivity Analyses
It is also important to consider the proposed project’s sensitivity to market conditions as well as
to the assumptions made in this report about the design. Figure 6 below shows the project’s economic
sensitivity to three key factors: reduction in product selling price, reduction in the number of doses sold,
and increased cost of manufacturing. A reduction in selling price has the expected effects with a 50%
decrease in price resulting in about a 50% decrease in NPV. However, it is unlikely that such a price
10

fluctuation would occur in this market, so this will not be much of a factor on the project’s profitability.
The number of doses sold could fluctuate somewhat if demand did not increase yearly as expected.
Again, though, this is a very stable market with a stable client base, and the number of doses sold is
unlikely to drop by a significant amount. The key point to consider here is that while the market is stable
for the current production process, it is yet unclear if the market will react favorably to a new
production method or if the market will be slow to accept a new production method as safe and
reliable. This could potentially lower the amount of doses that this project would be able to move in the
market and thus reduce profit.
The most important factor to examine is the cost of manufacturing. Some assumptions have
been made in this report in regards to the manufacturing process especially in determining how many
batches of product will be needed per year. The validity of these assumptions has not been tested
experimentally. This leaves uncertainty in the manufacturing cost calculations. Figure 6 shows that the
process is extremely robust in this area, though. A 50% increase in manufacturing costs has almost no
effect on the NPV. Even if costs were greatly understated, this should not affect the profitability of the
project.
The new production method seems to be economically profitable and robust. As long as the
market is thought to be open to new technologies and methods of production, project profitability
should not be a cause for concern for the Sf9 production platform.

Figure 6a
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Figure 6b

Figure 6c
Figure 6: Sensitivity of project NPV to a) price of vaccine on the market, b) number of doses sold, and c) manufacturing costs

X: Safety, Health, and Environmental Considerations
There are major health and safety concerns when dealing with vaccine production. However,
most of these concerns will not be new to the production facility simply because the expression
platform changes. Current operating procedures will be sufficient to handle most of the changes that
would occur. The cell culture media is chemically defined, so the facility will be animal free. The
production team will require additional training and development for using the new single-use
12

disposable equipment. Disposal procedures will need to be established to ensure safe disposal of all
single-use equipment. Existing waste management systems may prove sufficient for the new process.
However, preliminary tests should be conducted to ensure safe and reliable waste management. Facility
sterilization is still budgeted into the design economics as a safety measure even though most of the
equipment used in this design would be pre-sterilized single-use disposables.
XI: Conclusions and Recommendations
1. Influenza vaccine production by non-egg based platforms is a reasonable design consideration
based on its ability to meet and exceed market demand in a reasonable time period and its
economic viability.
2. Production of 60 million doses of influenza vaccine using an Sf9 insect cell expression platform
can be completed in three to four months economically in a facility similar to the design
proposed in this report.
3. Disposable equipment offers a viable alternative to traditional clean-in-place equipment. It is
easy to use, can decrease production times, and was not shown to have a major negative
economic impact on the design. The design herein employs disposable reactors, mixers, and
filtration equipment.
4. Considering recent market trends in the supply and distribution of the influenza vaccine,
production capabilities should be 60 million doses per year to control one third of the market
and be prepared to meet market needs during an outbreak.
5. Capital costs in this report are quite low due to the use of an existing facility. This should be
taken into account when considering the overall profitability of the project.
6. The economic analysis for the project is favorable with a NPV potential of $460 million for a 10
year project lifetime at a 50% IRR.
7. The project is economically robust in regards to selling price and manufacturing costs.
8. More research should be done on how the market will react to a new production method that is
not “time-tested.” Even if production rate is not a problem, moving the vaccine in the market
may be an issue using this new technology.
9. Few new safety considerations arise with the transition to an Sf9 expression platform. The
production team should be trained on any new disposable equipment employed in the process.
10. Existing waste treatment protocols should be tested with the new production method to see if
new equipment or protocol is required.
11. The next step in the design process is to conduct laboratory and pilot-scale tests to determine
more exact cell growth and virus growth profiles for more detailed designs in the future.
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XIV: Appendix A – Calculation Methodologies for Production
The density of the broth exiting the reactor was given as 1.06 g/mL. The assumption was made
that 1.00 g/mL could be accounted for by water, and that 0.02 g/mL could be accounted for by the cells
and the virus in the broth. The radius of an Sf9 cell is estimated at 16 μm before inoculation and 20 μm
when the virus is present in the cell [1]. The increase in volume is attributed to the virus, and a
percentage of the amount of virus in the cells is calculated to be 0.488. Assuming that 80% of the virus
produced in the reactor is active, the virus density is calculated by multiplying the overall density by the
infection rate and the percent virus to give a virus density of 0.0078 g/mL. Knowing that 60 μg of each
moiety is required per dose, the doses per mL of broth is calculated to be 130. The total dose production
allows for the calculation of total broth production. The volume of broth per batch is also known which
leads to the calculation of 12 batches per moiety for a total batch count of 36 for the trivalent vaccine.
The calculation is outlined in Table A-1 below.
Table A-1: Calculation methodology for determining the total number of batches required to meet
production requirements

Amount
Unit
Total broth density
1.06
g/mL
Density of cells and virus
0.02
g/mL
Sf9 cell radius pre-virus
16
um
Sf9 cell radius inoculated
20
um
Sf9 cell volume pre virus
17148.59 um^3
Sf9 cell volume inoculated
33493.33 um^3
Volume of virus
16344.75 um^3
Percentage virus
0.488
--Active virus fraction
0.8
--Active virus density
0.007808 g/mL
Moeity required for each dose 6.00E-05 g/mL
Doses per mL of broth
130.13 dose/mL
Total doses needed
6.00E+07 dose
Broth needed
4.61E+05
mL
Volume broth per batch
40000
mL
Batches required (each moeity)
11.53
batch
In addition, since each seed train and bioreactor cycle take 210 hours combined and there are
12 batches per moiety and 3 available seed train batches at once, the total time for a single moiety
production is 840 hours (35 days).
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XV: Appendix B - Complete Economics Analysis Table
Table B-1: Complete economics analysis table
End of Year (k)
Investment
Depreciation (dk)
FCIL-∑dk
Revenue
COM
(R-COM-dk)*(1-t)+dk
Cash Flow (CF)
Cumulative CF
Discounted CF
Cumulative Discounted CF

6
$
$
$
$
$
$
$
$
$
$

55,195.03
(0.00)
390,600,000.00
2,853,369.00
232,670,056.61
232,670,056.61
1,395,312,923.40
20,426,452.16
423,632,583.19

$
$
$
$
$
$
$
$
$
$

0
(958,247.00)
(958,247.00)
(958,247.00)
(958,247.00)
(958,247.00)

7
$
$
$
$
$
$
$
$
$
$

(0.00)
390,600,000.00
2,853,369.00
232,647,978.60
232,647,978.60
1,627,960,902.00
13,616,342.60
437,248,925.79

1
$
$
$
$
$
$
$
$
$
$

191,649.40
766,597.60
390,600,000.00
2,853,369.00
232,724,638.36
232,724,638.36
231,766,391.36
155,149,758.91
154,191,511.91

2
$
$
$
$
$
$
$
$
$
$

306,639.04
459,958.56
390,600,000.00
2,853,369.00
232,770,634.22
232,770,634.22
464,537,025.58
103,453,615.21
257,645,127.11

3
$
$
$
$
$
$
$
$
$
$

$
183,983.42 $
275,975.14 $
390,600,000.00 $
2,853,369.00 $
232,721,571.97 $
232,721,571.97 $
697,258,597.55 $
68,954,539.84 $
326,599,666.96 $

4
$
110,390.05 $
165,585.08 $
390,600,000.00 $
2,853,369.00 $
232,692,134.62 $
232,692,134.62 $
929,950,732.17 $
45,963,878.44 $
372,563,545.40 $

8
9
10
11
$
$
$
$
$
$
$
$
(0.00) $
958,247.00 $
958,247.00 $
958,247.00
390,600,000.00 $ 390,600,000.00
$ 390,600,000.00 $ 390,600,000.00 $
$
2,853,369.00 $
2,853,369.00 $
2,853,369.00 $
2,853,369.00
232,647,978.60 $ 232,647,978.60
$ 232,647,978.60 $ 232,647,978.60 $
232,647,978.60 $ 232,647,978.60
$ 232,647,978.60 $ 232,647,978.60 $
$ 1,860,608,880.60 $ 2,093,256,859.20 $ 2,325,904,837.80 $ 2,558,552,816.40
2,689,647.92
4,034,471.88 $
$
9,077,561.73 $
6,051,707.82 $
$ 446,326,487.52 $ 452,378,195.34 $
456,412,667.22 $ 459,102,315.14

16

5
110,390.05
55,195.03
390,600,000.00
2,853,369.00
232,692,134.62
232,692,134.62
1,162,642,866.79
30,642,585.63
403,206,131.03

